Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug;7(2):169-172.
doi: 10.3892/br.2017.939. Epub 2017 Jul 4.

The influence of D- chiro-inositol and D- myo-inositol in pregnant women with glucose intolerance

Domenico Dell'Edera  1 , Francesca Sarlo  1 , Arianna Allegretti  1 , Francesca Simone  1 , Maria Giovanna Lupo  1 , Annunziata Anna Epifania  1
Affiliations

The influence of D- chiro-inositol and D- myo-inositol in pregnant women with glucose intolerance

Domenico Dell'Edera et al. Biomed Rep. 2017 Aug.

Abstract

The aim of the present study was to demonstrate that the use of inositol and folic acid from the first trimester of pregnancy, counteracts the onset of gestational diabetes mellitus (GDM) in women at risk, preserving the infants from macrosomia, hypoglycemia and preterm delivery. The authors collected data from the pregnant women at the laboratory (Unit of Cytogenic and Molecular Genetics), from January 2014 to April 2016, all with first trimester fasting plasma glucose (FPG) >92 mg/dl. A total of 40 women were treated with 250 mg/day D-chiro-inositol, 1.75 g/day D-myo-inositol, 12.5 mg/day zinc, 10 mg/day methylsulfonylmethane, 400 µg/day 5-methyltetrahydrofolic acid. The other 43 women (control group) were treated with only 400 µg/day folic acid. The primary outcome measure was the incidence of maternal GDM. The secondary outcome measures were the incidence of fetal macrosomia, preterm delivery and neonatal hypoglycemia. At the 24th week of pregnancy, the incidence of maternal GDM was recorded in 18 women in the control group and in 5 women in the treated group [relative risk (RR)=3.35; 95% confidence interval (CI)=1.37-8.17; P=0.0028). A significant difference was observed between treated and control groups in terms of risk of macrosomia. A total of seven infants in the control group, and two in the treated group, weighed >4,000 g (RR=5,12; 95% CI=1.21-21.68; P=0.0099). No significant difference was identified between two groups, regarding the other two secondary outcomes, neonatal hypoglycemia (RR=4.650; 95% CI=0.57-38.11; P=0.1086) and preterm delivery (RR=1.74; 95% CI=0.83-3.66; P=0.1301). The current study demonstrated the potential benefit of supplementation with the association of D-chiro-inositol and D-myo-inositol in pregnant 'at risk' women, with first trimester FPG >92 mg/dl, in preventing the onset of maternal GDM and macrosomia in newborns.

Keywords: D-chiro-inositol; D-myo-inositol; fasting blood glucose; folic acid; gestational diabetes mellitus.

PubMed Disclaimer

References

    1. Vedavathi KJ, Swamy RM, Kanavi RS, Venkatesh G, Veerananna HB. Influence of gestational diabetes mellitus on fetal growth parameters. Int J Biol Med Res. 2011;2:832–834.
    1. Homko C, Sivan E, Chen X, Reece EA, Boden G. Insulin secretion during and after pregnancy in patients with gestational diabetes mellitus. J Clin Endocrinol Metab. 2001;86:568–573. doi: 10.1210/jcem.86.2.7137. - DOI - PubMed
    1. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Berkowitz K, Marroquin A, Goico J, Ochoa C, Azen SP. Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. Diabetes. 2000;49:782–788. doi: 10.2337/diabetes.49.5.782. - DOI - PubMed
    1. Giugliano E, Cagnazzo E, Giugliano B, Caserta D, Moscarini M, Marci R. The Prevention of Gestational Diabetes. J Diabetes Metab. 2013;4:286.
    1. Magon N, Seshiah V. Gestational diabetes mellitus: Non-insulin management. Indian J Endocrinol Metab. 2011;15:284–293. doi: 10.4103/2230-8210.85580. - DOI - PMC - PubMed